Shockwave Medical Croissance future

Future contrôle des critères 3/6

Shockwave Medical devrait augmenter ses bénéfices et son chiffre d'affaires de 18.4% et de 16.3% par an respectivement. Le BPA devrait croître de de 16.3% par an. Le rendement des capitaux propres devrait être 18.8% dans 3 ans.

Informations clés

18.4%

Taux de croissance des bénéfices

16.3%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.1%
Taux de croissance des recettes	16.3%
Rendement futur des capitaux propres	18.8%
Couverture par les analystes	Good
Dernière mise à jour	28 May 2024

Mises à jour récentes de la croissance future

Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 18

Recent updates

Shockwave Medical, Inc.'s (NASDAQ:SWAV) 28% Jump Shows Its Popularity With Investors

Apr 06

Is Now An Opportune Moment To Examine Shockwave Medical, Inc. (NASDAQ:SWAV)?

Mar 24

Shockwave Medical: Opening Arteries, Delivering Returns

Feb 28

Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 18

There's Been No Shortage Of Growth Recently For Shockwave Medical's (NASDAQ:SWAV) Returns On Capital

Feb 06

Calculating The Fair Value Of Shockwave Medical, Inc. (NASDAQ:SWAV)

Jan 24

Some Shareholders Feeling Restless Over Shockwave Medical, Inc.'s (NASDAQ:SWAV) P/E Ratio

Jan 09

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:SWAV - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	1,357	299	318	366	9
12/31/2025	1,136	242	239	260	13
12/31/2024	929	210	417	265	7
3/31/2024	788	163	166	198	N/A
12/31/2023	730	147	165	196	N/A
9/30/2023	671	244	143	177	N/A
6/30/2023	617	244	126	161	N/A
3/31/2023	557	241	121	150	N/A
12/31/2022	490	216	93	118	N/A
9/30/2022	430	88	69	86	N/A
6/30/2022	364	55	48	61	N/A
3/31/2022	299	29	23	34	N/A
12/31/2021	237	-9	3	15	N/A
9/30/2021	176	-38	-29	-18	N/A
6/30/2021	130	-53	-53	-44	N/A
3/31/2021	84	-71	-75	-64	N/A
12/31/2020	68	-66	-83	-71	N/A
9/30/2020	59	-65	-83	-71	N/A
6/30/2020	51	-65	-77	-66	N/A
3/31/2020	51	-57	-66	-58	N/A
12/31/2019	43	-51	-52	-48	N/A
9/30/2019	34	-48	-48	-45	N/A
6/30/2019	26	-45	-47	-45	N/A
3/31/2019	18	-44	-47	-45	N/A
12/31/2018	12	-41	-43	-41	N/A
12/31/2017	2	-31	N/A	-30	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de SWAV ( 18.4% par an) est supérieure au taux d'épargne ( 2.4% ).

Bénéfices vs marché: Les bénéfices de SWAV ( 18.4% par an) devraient croître plus rapidement que le marché US ( 15.4% par an).

Croissance élevée des bénéfices: Les bénéfices de SWAV devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de SWAV ( 16.3% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de SWAV ( 16.3% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de SWAV devrait être faible dans 3 ans ( 18.8 %).

Shockwave Medical Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

Price target increased by 7.7% to US$302

Price target increased by 9.7% to US$286

Consensus EPS estimates increase by 12%

Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

Recent updates

Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024

Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter

Shockwave Medical Files Form 15

Shockwave's Common Stock Ceases Trading on NASDAQ

Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shockwave Medical, Inc., Annual General Meeting, May 29, 2024

Price target increased by 7.7% to US$302

Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Shockwave Medical, Inc.'s (NASDAQ:SWAV) 28% Jump Shows Its Popularity With Investors

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion.

Price target increased by 9.7% to US$286

Insufficient new directors

Johnson & Johnson Reportedly Considers Deal for Shockwave Medical

Chief Commercial Officer notifies of intention to sell stock

Is Now An Opportune Moment To Examine Shockwave Medical, Inc. (NASDAQ:SWAV)?

Independent Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock

Shockwave Medical: Opening Arteries, Delivering Returns

New minor risk - Shareholder dilution

Independent Director recently sold US$15m worth of stock

Now 21% undervalued

Consensus EPS estimates increase by 12%

President exercised options and sold US$2.3m worth of stock

Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Full year 2023 earnings: EPS exceeds analyst expectations

Shockwave Medical, Inc. Provides Earnings Guidance for 2024

There's Been No Shortage Of Growth Recently For Shockwave Medical's (NASDAQ:SWAV) Returns On Capital

Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024

Chief Commercial Officer notifies of intention to sell stock

Calculating The Fair Value Of Shockwave Medical, Inc. (NASDAQ:SWAV)

President notifies of intention to sell stock

Shockwave Medical, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Some Shareholders Feeling Restless Over Shockwave Medical, Inc.'s (NASDAQ:SWAV) P/E Ratio

President notifies of intention to sell stock

Is Shockwave Medical (NASDAQ:SWAV) A Risky Investment?

Chief Commercial Officer notifies of intention to sell stock

President exercised options and sold US$922k worth of stock

Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?

Now 21% undervalued after recent price drop

President notifies of intention to sell stock

What Is Shockwave Medical, Inc.'s (NASDAQ:SWAV) Share Price Doing?

Investor sentiment deteriorates as stock falls 25%

Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy

Now 22% undervalued after recent price drop

Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to US$241

Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States

Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Is Shockwave Medical, Inc. (NASDAQ:SWAV) Trading At A 50% Discount?

President notifies of intention to sell stock

Shockwave Medical (NASDAQ:SWAV) Is Very Good At Capital Allocation

Shockwave Medical (NASDAQ:SWAV) Has A Rock Solid Balance Sheet

President notifies of intention to sell stock

Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer

Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer

Do Shockwave Medical's (NASDAQ:SWAV) Earnings Warrant Your Attention?

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 10%, revenue upgraded

Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director notifies of intention to sell stock

When Should You Buy Shockwave Medical, Inc. (NASDAQ:SWAV)?

We Think Shockwave Medical (NASDAQ:SWAV) Might Have The DNA Of A Multi-Bagger

Chief Commercial Officer notifies of intention to sell stock